Azitra reported Q2 2024 financial results and provided pipeline updates. Revenue was $7,500, down from $172,000 in Q2 2023. R&D expenses increased to $1.1M from $0.8M YoY, while G&A expenses rose to $1.5M from $0.8M. Net loss narrowed to $2.6M from $5.1M. Cash position was $0.8M as of June 30, 2024.The company completed a $10M follow-on offering, extending cash runway into 2025. Key upcoming milestones include dosing the first Netherton syndrome patient with ATR-12 in Q3 2024, filing an IND for ATR-04 in EGFRi rash, and initiating its first-in-human trial by year-end. Azitra expects to report initial ATR-12 safety data and provide a Bayer license agreement update by year-end 2024.CEO Francisco Salva expressed confidence in achieving significant milestones in H2 2024 and beyond. The company anticipates reporting topline data from the ATR-12 Phase 1b trial in Netherton syndrome by mid-2025, aiming to demonstrate proof of concept for its innovative approach to this rare skin disorder.

Azitra reported Q2 2024 financial results and provided pipeline updates. Revenue was $7,500, down from $172,000 in Q2 2023. R&D expenses increased to $1.1M from $0.8M YoY, while G&A expenses rose to $1.5M from $0.8M. Net loss narrowed to $2.6M from $5.1M. Cash position was $0.8M as of June 30, 2024.The company completed a $10M follow-on offering, extending cash runway into 2025. Key upcoming milestones include dosing the first Netherton syndrome patient with ATR-12 in Q3 2024, filing an IND for ATR-04 in EGFRi rash, and initiating its first-in-human trial by year-end. Azitra expects to report initial ATR-12 safety data and provide a Bayer license agreement update by year-end 2024.CEO Francisco Salva expressed confidence in achieving significant milestones in H2 2024 and beyond. The company anticipates reporting topline data from the ATR-12 Phase 1b trial in Netherton syndrome by mid-2025, aiming to demonstrate proof of concept for its innovative approach to this rare skin disorder.